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mended threshold of willingness-to-pay (£20,000 per QALY) in conjunction with 
the costs of each route to report the incremental net monetary benefits (INB) of 
nutritional support via PN versus EN. Results: Mean QoL at 90-days and one year 
was similar between the randomised groups. At one year, the PN group had higher 
costs (£1,580 [95% CI -£792 to £3,951]), similar QALYs (0.013 [95% CI -0.014 to 0.040]) 
and negative INB (-£1,320 [95% CI -£3,709 to £1,069]) compared to the EN group. 
When a lifetime time horizon is taken, the INB of PN was positive but with con-
siderable uncertainty surrounding the result (£440 [95% CI -£3,586 to £4,466]). The 
probabilities that PN is more cost effective were 14% (1 year) and 58% (lifetime), 
respectively. ConClusions: For critically ill adult patients, providing nutritional 
support via PN versus EN is unlikely to be cost-effective. However, it should be 
recognised that considerable uncertainty surrounds the cost-effectiveness results, 
especially when projected over the patient’s lifetime.
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objeCtives: Japanese government is now trying to introduce cost-effectiveness 
analysis into its healthcare system because of severe budget constraint. It would 
be important to elucidate the basic attitude of physicians towards health care 
resource allocation on this occasion. Methods: A web-based survey for physi-
cians was carried out in Japan, adjusting for age, sex, specialty, and hospital scale, 
between February and March in 2015. The questionnaire consisted of two main 
inquiries and related questions. The 1st question was about medical decision to 
choose between two screening test for a population at low risk for colon cancer. 
Test A was more cost effective than test B, but was too expensive to be given to 
everyone in the population. The option 1 was that all subjects received test B and 
subsequently the death of 1,000 people was prevented, while the option 2 was that 
a half of the subjects were selected by lottery and received test A, preventing the 
death of 1,100 people as a consequence. The 2ndquestion was concerning prior-
ity setting between two types of diseases differing the treatment cost(disease A: 
¥10 million per patient; disease B: ¥2 million per patient). The physicians were 
asked to choose some possible combinations of numbers of people treated if the 
total expenditure were limited to 100 million yen. Results: Out of 1,089(male/
female= 891/198) respondents, 699 chose the option 1 in the 1st question. In 
question 2, 187 chose the least utilitarian combination(A;8, B;10), 125 chose 2nd 
combination(A;6, B;20), 277 chose 3rd one(A;4, B;30), 76 chose 4thone(A;2, B;40), and 
424 chose the most utilitarian option(A;0, B;50). ConClusions: We investigated 
the basic attitude of physicians towards healthcare resource allocation in Japan 
in a setting of budget constraints, which revealed that fairly extreme utilitarian 
selection was the more popular among them than expected.
PHP105
general assessment Of unlicensed medicine usage in turkey
Dogan E1, Kockaya G2, Tuna E3, Yenilmez FB3, Vural IM1, Akbulat A1, Artiran G1, Tatar M3, 
Unal O1
1Turkish Medicines and Medical Devices Agency, Ankara, Turkey, 2Health Economics and Policy 
Association, Ankara, Turkey, 3Hacettepe University, Ankara, Turkey
objeCtives: The Turkish Medicines and Medical Devices Agency (TMMDA) gives 
permission of unlicensed medicine use by patient basis. Authorized wholesalers 
including Turkish Pharmacists’ Association (TPA) can import the drugs based on 
the TMMDA’s permission. These medicines are reimbursed by the Social Security 
Institution (SSI), the main reimbursement agency in Turkey Until 2014 when wholesal-
ers were also authorized, pharmaceuticals under this status could only be imported 
by the Turkish Pharmacists’ Association (TPA). The aim of this study is to understand 
the trends in unlicensed medicine consumption between 2011 and 2013 when the 
TPA was the only authorized supplier. Methods: Consumption data of the top 100 
imported unlicensed medicines with the highest sales share in total expenses of 
imported off-label use was taken from the TMMDA computer database. Descriptive 
analysis was conducted. Results: The analysis showed that cost of the top 100 
imported unlicensed medicines increased in every year from 232 billion TL to 747 
billion TL between 2011 and 2013, respectively. According to the ATC code, L group 
(Antineoplastic and immunomodulating agents) had the highest number of active 
ingredients in top 100. In addition to this, the number of L group medicines rose from 
37 to 55 between 2011 and 2013. Also the average cost per box increased from 2.837 
TL to 5.308 TL in the same period. ConClusions: The cost of imported unlicensed 
medicines use increased every year in Turkey. Some cost-containment measures 
(especially for antineoplastic medicines) should be taken to reduce this cost without 
risking the patients’ access to innovative medicines.
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objeCtives: To determine the disease focus of all papers indexed in the PubMed 
database that reported costs or resource use as an outcome and were published 
in 2014. Methods: An evidence surveillance process was established based on a 
systematic search of PubMed, using key words relevant to the costs or resource use 
associated with healthcare or disease and limited to studies published in English, 
in humans, with abstracts, and either clinical trials or observational, comparative 
or multicentre studies. The surveillance incorporated all studies published from 
2010 and was updated weekly. Abstracts identified by the search of studies that 
reported data on economic burden outcomes were indexed according to disease 
area, using the chapter categorisation from ICD-10 as a framework. To account 
able fee for a given procedure) and obstetricians/gynecologists (+31.9%), while the 
lowest rates of surcharges were billed by nephrologists (< +1%) and pulmonologists 
(+3.0%). ConClusions: This study confirms that Open DAMIR data can provide a 
more nuanced estimation of the cost of certain care services than is commonly used 
for health economic evaluation in France. While the publication of this database 
represents a step forward, the inclusion of select additional variables to the database 
would further increase its usefulness in health economic assessment.
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objeCtives: Entering the fiscal adjustment program in 2010, one of the primary 
mandates for Greece was to reduce public pharmaceutical expenditure from the then 
current 2.2% of GDP to 1%. Within this context, a series of policies (increased copay-
ments, price-cuts, delisting, rebates, clawbacks etc) were enforced. As a result, 2014 
public pharmaceutical expenditure did reach 1% of GDP, but following a significant 
increase in private spending. In this light, the purpose of this study is to investigate 
the macroeconomic trends in pharma expenditure during 2009-2014 and estimate 
the public/private mix of contributions. Methods: Aggregate data on outpatient 
sales by the Greek National Medicines Agency for 2009-2014, formed the basis of the 
analysis. To account for price changes, expenditures were adjusted to 2014 constant 
prices, by estimating and using the weighted average price/box for 2014 as deflator. 
Expenditures were allocated to public or private payers according to official macro-
economic reports of the third-party payers for 2009 and via publicly available subac-
counts for 2014. Results: Pharmaceutical expenditure totaled 6.12 billion euros in 
2009 (€ 5.1 billion public, € 0.09 billion rebates, € 0.91 billion private) and € 3.57 billion 
in 2014 (€ 2 billion public expenditure, € 428 million in rebates/clawbacks, € 1.14 billion 
private). Average price per box sold fell by 36.2% during 2009-2014. Thus, when adjust-
ing for prices, the respective figures are € 3.90 and € 3.57 billion. Public/private mix was 
85%/15% for 2009 and 64%/36% for 2014 (excluding rebates). A total of a € 0.93 billion 
shift towards patients and companies (€ 564million towards patients and € 366million 
as additional rebates/clawbacks) resulted in achieving the fiscal target of 1% of GDP 
for 2014 public pharma expenditure. ConClusions: Despite the rhetoric and the 
reforms implemented, total outpatient pharmaceutical volumes dropped by only 8% 
during 2009-2014. Fiscal adjustment was achieved by cost-shifting to private payers, 
primarily to patients, raising concerns about equity in access and social solidarity.
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objeCtives: To study the direct costs of drug-related morbidity using three 
sources of data; experts opinion, medical records and survey responses from the 
general public. Methods: Probabilities for clinical outcomes of drug-related mor-
bidity were estimated based on expert opinions from 29 pharmacists and 19 phy-
sicians. Costs were assigned using Cost Per Patient register data to resource-use 
from drug-related morbidity identified in the medical records of 4970 randomly 
selected individuals from a Swedish county during a three-month study period. A 
postal survey was sent to a random sample of the Swedish population. Resource-
use resulting from drug-related morbidity reported during one month by 7099 
survey respondents, and by the expert panels, were assigned unit costs based 
on national costs statistics. All cost estimates were prevalence-based. Results: 
The expert panels reported drug-related morbidity to be common, and to cause 
considerable healthcare resource use representing up to 20% of all costs to the 
healthcare system. Drug-related morbidity identified in medical records were 
estimated to cause 1.5% of all drug costs and 9.5% of healthcare costs, and costs 
occurred in all parts of the healthcare system. According to survey responses, two 
types of drug-related morbidity - adverse drug reactions and sub-therapeutic effect 
of medication therapy - caused 0.5% of all drug costs and 6.1% of all healthcare 
costs. In addition, respondents reported informal care, lost leisure time, and sick-
leave resulting from drug-related morbidity which were unfeasible to assign costs 
in these studies. ConClusions: Based on these results, drug-related morbidity 
causes considerable resource use and harm in the general public, and throughout 
the healthcare system; in primary care, other outpatient care and inpatient care. 
Moreover, it appears that there are additional resource use due to drug-related 
morbidity, such as productivity loss, which should be included for a full account 
of the economic impact of drug-related morbidity.
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objeCtives: Early and appropriate nutritional support is recommended for criti-
cally ill patients. Evidence is conflicting regarding the optimum route of deliv-
ery and robust cost-effectiveness evidence is lacking. The objective of the study 
was to evaluate the cost-effectiveness of early nutritional support via the par-
enteral (PN) versus the enteral (EN) route in critically ill adults. Methods: We 
undertook a cost-effectiveness analysis (CEA) using data from a large, pragmatic, 
multi-centre RCT that recruited patients from 33 English adult, general critical 
care units. Resource use and outcome data on 2388 trial patients were used to 
report cost-effectiveness at 90-days and at one year, and to project lifetime cost-
effectiveness. The CEA used information on Health-related Quality of Life (QoL) 
at 90-days and at one year combined with information on vital status to report 
Quality-Adjusted Life Years (QALYs). Each QALY was valued using the NICE recom-
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Several KPIs were examined, but the study focuses on the mean pharmaceutical 
cost per patient, which was then adjusted to the case mix of the units, by using a 
hospital clinical weight indicator, estimated as the weighted average of particular 
incidents, based on GR-DRG data. The results were statistically analysed, in order 
to group the changes, before and after the indicator’s adjustment, per hospital size 
category and assess hospitals’ relative ranking. Results: The results reveal that 
there was a significant -but diminishing as the bed number increases- rise in the 
mean pharmaceutical cost per patient for three categories (25.49%, 14.23%, 11.74% 
increase for hospitals with less than 100, 101-250 and 251-400 beds, respectively) 
after the indicator was adjusted to the hospitals’ clinical workload. For hospitals 
with more than 400 beds, the mean pharmaceutical cost per patient decreased 
by 15.38%, after the adjustment. The results also indicate significant changes in 
hospital ranking, even within the 4 categories, ranging from a 34 places ranking 
rise for Onassis Cardiac Surgery Centre, to a 21 places ranking drop for the G.H. of 
Thessaloniki ‘Agios Dimitrios’. ConClusions: Hospitals with more severe than 
average incidents, (cancer hospitals, cardiac surgery centres, etc) improved their 
performance and relative ranking, while small health centres and regional hospi-
tals reported worse results after the indicators’ adjustment. The study concludes 
that clinical workload should be incorporated in hospitals’ pharmaceutical cost 
assessment.
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objeCtives: The objective of this work is to set a cost benefit analysis of the use 
of fibrin sealant patch as supportive treatment in surgery for improvement of 
hemostasis, to promote tissue sealing and for suture support in surgery in those 
cases where standard techniques are not adequate. Methods: Efficacy data were 
obtained from a systematic literature review. The analysis of the costs of hospitali-
zation was conducted on the basis of detection of actual costs, observed from the 
point of view of the hospital. We performed a cost benefit analysis of the use of fibrin 
sealant patch valuing the hospitalization and the consequent use of resources. The 
results of the economic evaluation were subjected to sensitivity analysis, building a 
stochastic simulation with 1000 repetitions within a normal distribution. Results: 
In the group of patients treated with fibrin sealant patch it was observed the 
decrease of the duration of hospitalization vs. the group of patients treated with 
standard techniques: on average 2.66 days, within a range between 0.55 and 11.80 
days. The cost per day of hospitalization was estimated at Euro 206.00: this led to 
a saving in terms of lower costs for the hospital, quantifiable in 549 Euro, from a 
minimum of 103 Euro and a maximum of 2431 Euro. The use of fibrin sealant patch 
led then an average savings of about 304.00 Euro per patient with a cost-benefit ratio 
equal to 2.24 (min. 00.42 - max. 9.93). Overall the results of the sensitivity statistics 
confirm a lower length of stay associated with fibrin sealant patch than standard 
care. ConClusions: The analysis shows the positive role of fibrin sealant patch 
as supportive treatment in surgery where standard techniques are revealed not 
adequate, with decreased postoperative complications, shorter hospital stays and 
reducing hospital costs.
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objeCtives: Personalized medicine (PM) consists of a customized approach consid-
ering individual biological and genetic characteristics to prevent, diagnose or treat 
a medical condition. Although health benefits of PM have been demonstrated, its 
economic impact is not established. The aim of this review was to explore its cost-
effectiveness and summarize the key parameters in every therapeutically health 
areas. Methods: A systematic review of economic evaluations was performed 
using the PICO method. Population consisted of patients who might benefit from 
PM; intervention and comparators were PM and usual care and outcomes were 
results of economic evaluations. The literature search was performed with the NHS 
EED filters using Medline, Embase and Pubmed from 2004 to 2014. Eligible articles 
were economic evaluations, with preventive, diagnostic or therapeutic interven-
tions in PM. Results: A total of 76,488 studies were identified and 213 met the 
inclusion criteria. Cost-utility studies were the most frequent (60.1%), followed 
by cost-effectiveness studies (32.1%) with a healthcare-payer perspective (67.9%). 
Time horizon varied between 28 days and lifetime. Cancer was the most evaluated 
therapeutic field (46.9%) followed by cardiovascular diseases (19.2%) and neurologic 
and psychological diseases (10.3%). A total of 39.9% of the studies were conducted 
in the United States. Adjusted 2015USD ICERs varied from dominant to $9,780759 
per quality adjusted life year (QALY). Among these, 44% have an ICER of $50,000/
QALY or less, while 57% have an ICER of $100,000/QALY or less. Overall, a total of 
147 studies compared their ICER to the reference threshold established by their 
country. Among the ICERs presented, 60.2% were reported as cost-effective (15.3% 
were dominant) and 39.8% non cost-effective. ConClusions: Despite a high het-
erogeneity among the studies, most of them suggest that personalized medicine 
could be cost-effective.
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for the delay in indexing of publications, we included all studies with a publica-
tion date of 2014 that were indexed in PubMed up to 1 June 2015. Results: The 
search identified 1,870 articles published in 2014. Of these, 975 met the inclusion 
criteria and were subcategorised according to topic. The greatest number, 13%, 
were conducted in patients with cardiovascular diseases, with 11% in musculo-
skeletal disorders, 10% each in cancer and digestive disorders, 8% in mental health 
disorders, 7% each in infective disease or acute care, and 6% each in respiratory, 
endocrine and urogenital disorders, and in general populations or healthcare set-
tings. All other disease areas were relatively underrepresented, accounting for 2% 
or fewer of the relevant publications. ConClusions: Despite product pipelines 
being weighted towards new cancer drugs and the challenges in demonstrating 
their cost-effectiveness, cancers are relatively under-represented in recent stud-
ies assessing economic burden. The reasons why costs may be less important an 
outcome in cancer than in cardiovascular or musculoskeletal diseases are unclear, 
but may reflect a more established, often generic or surgical, therapeutic portfolio.
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objeCtives: Ultra orphan therapies are indicated for rare diseases affecting less 
than a few thousand patients. The annual and lifetime per patient cost of these 
treatments have generated controversy and policy questions regarding cost effec-
tiveness and reimbursement. The objective of this analysis was to review all avail-
able cost effectiveness studies and develop lessons for policy development for ultra 
orphan therapies. Methods: Fifteen European Medicines Agency (EMA) and Food 
and Drug Administration (FDA) approved ultra orphan drugs were identified and 
reviewed for their published cost effectiveness through studies in peer-reviewed 
journals and Health Technology Assessments (HTAs). Data was collected for: (1) 
Product (2) Indication (3) Model design and assumptions (4) Author of the analy-
sis (manufacturer, HTA or academic group) (5) Cost effectiveness results and (5) 
Sensitivity analysis results. All cost effectiveness ratios were converted to 2013 US 
dollar amounts using historical currency conversion rates. Results: For fifteen 
EMA and FDA approved ultra orphan therapies, eight cost effectiveness studies 
were identified for seven products (50%). Four of these studies were conducted by 
the sponsor (as part of the HTA submission), two were conducted by HTAs and two 
were from academic groups. All models were developed for a life time horizon. 
In the base case scenario, the median base case incremental cost effectiveness 
ratio (ICER) was $591,200 per quality adjusted life years (QALYs) (range: $391,120 
to $7,425,000). The sensitivity analyses results had a median ICER of $1,958,674 
per QALY, with a maximum ICER of $10,395,000. All reported ICERs exceeded the 
maximum accepted thresholds for end of life care therapies. ConClusions: 
Review of cost effectiveness studies for ultra orphan therapies shows that none 
were able to show ICERs within typical thresholds. These results suggest a need 
for new policy regarding acceptable threshold, or type of models for assessing the 
cost effectiveness of ultra orphan therapies.
PHP108
Off-Patent drugs cOnsumPtiOn and exPenditures in italy: 2009-2013
Daniel F1, Aiello A1, D’Ausilio A1, Toumi M2
1Creativ Ceutical, Milano, Italy, 2Université Aix Marseilles, Marseilles, France
objeCtives: As in most European countries, spending on pharmaceuticals has 
also been cut in recent years in Italy through a series of measures, including price 
reduction and boosting of off-patent drugs prescription. Laws 338/2000 and 405/2001 
incentivised the use of generic drugs and introduced patients’ co-payment if they 
preferred a branded vs off-patent drug. The aim of this study was to analyse the 
consumption and expenditure trend for off-patent drugs in Italy since the intro-
duction of these new measures. Methods: Off-patent (branded and unbranded) 
drug consumption and expenditure indicators from 2004 (first year in which net 
expenditure was available) to 2013 (last available year) were analysed from the 
Observatory on the Use of Medicines (OSMED) published reports. Results: In 2004 
consumption by defined daily dose (DDD) per 1,000 habitants was 166.8 (21.7% on 
total DDD), while in 2013, it was 663.0 (64.3% on total DDD) for territorial drugs. 
Per-capita expenditure was € 22 (10.1% of net territorial expenditures) in 2004 and 
€ 62.4 in 2013 (41.5% of net territorial expenditure). Such results were mainly due 
to the higher number of off-patent drugs available on the market and not only to 
increased use of generic drugs. In 2004, the percentage of unbranded drugs was 
1.9% and raised until 14.9% in 2013. Despite such growth, Italy was in 2013 the 
third European country (behind Greece and Ireland) for expenditure on branded 
drugs, with a very low uptake vs Germany, France, Spain and UK showing an inci-
dence of generic territorial drug expenditure between 30 and 40%. ConClusions: 
Consumption and expenditure on off-patent drugs has increased in the last 10 years 
in Italy, however the unbranded drugs uptake is still very low when compared with 
other European countries.
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objeCtives: To examine how hospitals’ pharmaceutical cost changes when clinical 
workload indicators are incorporated in the measurement and provide corrective 
estimates to the comparative performance assessment of the MoH for Greek NHS 
hospitals, for 2013. Methods: The study includes annual detailed financial and 
operational data, as recorded by the MoH’s BI system, ESY.net, and analytical data 
on the type of incidents (based on GR-DRGs) recorded, for 129 Greek NHS hospitals. 
